达格列净联合沙格列汀治疗的2型糖尿病患者混合餐后β细胞功能、肠促胰素效应及葡萄糖动力学
在二甲双胍控制不佳的2型糖尿病患者中,评估沙格列汀联合达格列净对混合餐后激素和代谢反应的影响。联合治疗较单药显著降低空腹和餐后血糖,改善胰岛素分泌率、胰岛素敏感性、GLP-1水平和葡萄糖清除率。
要点
- 联合治疗第3天空腹和餐后血糖降幅大于沙格列汀或达格列净单药。
- 联合治疗改善β细胞功能、胰岛素敏感性及GLP-1水平。
- 第4周联合治疗组胰岛素分泌率和敏感性进一步增加。
核心结论
- 沙格列汀联合达格列净较达格列净或沙格列汀单药提供更优血糖控制,并改善β细胞功能、胰岛素敏感性、GLP-1可用性和葡萄糖清除。
研究设计与样本
- 45例二甲双胍控制不佳的2型糖尿病患者(年龄58±8岁;HbA1c 58±6 mmol/mol;BMI 30.7±3.2 kg/m2),在基线及沙格列汀5 mg、达格列净10 mg或沙格列汀5 mg联合达格列净10 mg治疗3天和28天后,采用加双示踪葡萄糖的混合餐耐量试验评估葡萄糖代谢、胰岛素分泌和敏感性。
主要发现
- 第3天,联合治疗组空腹和平均混合餐耐量试验血糖分别降低31.1±1.6和91.5±12.4 mg/dL,降幅大于沙格列汀组(7.1±2.1和53±10.5 mg/dL)或达格列净组(17.0±1.1和42.6±10.0 mg/dL,P<0.001)。
- 胰岛素分泌率联合治疗组增加75%,沙格列汀组增加11%,达格列净组增加3%;胰岛素敏感性分别增加2.2±1.7、0.4±0.7和0.4±0.4 mg·kg-1·min-1(P<0.007)。
- 联合治疗组平均GLP-1高于沙格列汀或达格列净单药组;空腹胰高血糖素在达格列净和联合治疗组升高,沙格列汀组未升高;空腹内源性葡萄糖生成在联合治疗和达格列净组升高。
- 混合餐耐量试验期间,联合治疗组内源性葡萄糖生成抑制48%,沙格列汀组44%(P=0.02),达格列净组34%(P=0.2);联合治疗组葡萄糖代谢清除率增加更多。
- 第4周,联合治疗组胰岛素分泌率、β细胞葡萄糖敏感性和胰岛素敏感性进一步增加(P=0.02),GLP-1、胰高血糖素、空腹或混合餐耐量试验内源性葡萄糖生成及葡萄糖代谢清除率无额外变化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To explore the complementary effects of a combination of dipeptidyl peptidase 4 and sodium-glucose cotransporter 2 inhibitors added to metformin on hormonal and metabolic responses to meal ingestion. RESEARCH DESIGN AND METHODS: Forty-five patients (age 58 ± 8 years; HbA1c 58 ± 6 mmol/mol; BMI 30.7 ± 3.2 kg/m2) with type 2 diabetes uncontrolled with metformin were evaluated at baseline and 3 and 28 days after 5 mg saxagliptin (SAXA), 10 mg dapagliflozin (DAPA), or 5 mg saxagliptin plus 10 mg dapagliflozin (SAXA+DAPA) using a mixed-meal tolerance test (MMTT) spiked with dual-tracer glucose to assess glucose metabolism, insulin secretion, and sensitivity. RESULTS: At day 3, fasting and mean MMTT glucose levels were lower with SAXA+DAPA (-31.1 ± 1.6 and -91.5 ± 12.4 mg/dL) than with SAXA (-7.1 ± 2.1 and -53 ± 10.5 mg/dL) or DAPA (-17.0 ± 1.1 and -42.6 ± 10.0 mg/dL, respectively; P < 0.001). Insulin secretion rate (SAXA+DAPA +75%; SAXA +11%; DAPA +3%) and insulin sensitivity (+2.2 ± 1.7, +0.4 ± 0.7, and +0.4 ± 0.4 mg ⋅ kg-1⋅ min-1, respectively) improved with SAXA+DAPA (P < 0.007). Mean glucagon-like peptide 1 (GLP-1) was higher with SAXA+DAPA than with SAXA or DAPA. Fasting glucagon increased with DAPA and SAXA+DAPA but not with SAXA. Fasting endogenous glucose production (EGP) increased with SAXA+DAPA and DAPA. During MMTT, EGP suppression was greater (48%) with SAXA+DAPA (vs. SAXA 44%; P = 0.02 or DAPA 34%; P = 0.2). Metabolic clearance rate of glucose (MCRglu) increased more with SAXA+DAPA. At week 4, insulin secretion rate, β-cell glucose sensitivity, and insulin sensitivity had further increased in the SAXA+DAPA group (P = 0.02), with no additional changes in GLP-1, glucagon, fasting or MMTT EGP, or MCRglu. CONCLUSIONS: SAXA+DAPA provided superior glycemic control compared with DAPA or SAXA, with improved β-cell function, insulin sensitivity, GLP-1 availability, and glucose clearance.
引用
- Daniele G, Tura A, Brocchi A, et al. β-Cell Function, Incretin Effect, and Glucose Kinetics in Response to a Mixed Meal in Patients With Type 2 Diabetes Treated With Dapagliflozin Plus Saxagliptin. Diabetes Care. 2024. PMID: 38652656. doi:10.2337/dc23-2051
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。